NSABP FC-11
NSABP FC-11
A Phase II Study Evaluating the Combination of Neratinib Plus Trastuzumab or Neratinib Plus Cetuximab in Patients with "Quadruple Wild-Type" (KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Based on HER2 Status: Amplified, Non-Amplified (Wild-Type) or Mutated
Protocol Chair: Shannon Puhalla, MD
Protocol Officer: Carmen Allegra, MD
Patient Population:
Patients with KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer
Target Accrual: 35 patients
Status: Active, Not Recruiting
ClinicialTrials.gov Identifier: NCT03457896
A Phase II Study Evaluating the Combination of Neratinib Plus Trastuzumab or Neratinib Plus Cetuximab in Patients with "Quadruple Wild-Type" (KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Based on HER2 Status: Amplified, Non-Amplified (Wild-Type) or Mutated
Protocol Chair: Shannon Puhalla, MD
Protocol Officer: Carmen Allegra, MD
Patient Population:
Patients with KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer
Target Accrual: 35 patients
Status: Active, Not Recruiting
ClinicialTrials.gov Identifier: NCT03457896